Early outcomes comparing induction with antithymocyte globulin vs alemtuzumab in two steroid-avoidance protocols in pediatric renal transplantation.

Puliyanda, Dechu P; Pizzo, Helen; Rodig, Nancy; Somers, Michael J G

Puliyanda, Dechu P; Pizzo, Helen; Rodig, Nancy; Somers, Michael J G.

Affiliation

Puliyanda DP; Pediatric Nephrology and Transplant Immunology, Cedars-Sinai Medical Center, Los Angeles, California, United States.
Pizzo H; Pediatric Nephrology and Transplant Immunology, Cedars-Sinai Medical Center, Los Angeles, California, United States.
Rodig N; Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Somers MJG; Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.

Pediatr Transplant ; 24(3): e13685, 2020 05.

Article in En | MEDLINE | ID: mdl-32112514

Subject(s)

Alemtuzumab/therapeutic use; Antilymphocyte Serum/therapeutic use; Graft Rejection/prevention & control; Immunosuppressive Agents/therapeutic use; Induction Chemotherapy/methods; Kidney Transplantation; Adolescent; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Male; Steroids; Treatment Outcome

Key words

ATG; alemtuzumab; graft outcome; neutropenia

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Kidney Transplantation / Induction Chemotherapy / Alemtuzumab / Graft Rejection / Immunosuppressive Agents / Antilymphocyte Serum Type of study: Clinical_trials / Guideline Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Language: En Journal: Pediatr Transplant Journal subject: PEDIATRIA / TRANSPLANTE Year: 2020 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google